Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /
Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.Hungarian patients with inflammatory bowel disease were interviewed after a mandatory non-medical switch from an infliximab (IFX) originator to a...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | EXPERT OPINION ON BIOLOGICAL THERAPY
23 No. 8 |
| Tárgyszavak: | |
| doi: | 10.1080/14712598.2023.2211204 |
| mtmt: | 33826696 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/27844 |
| LEADER | 02632nab a2200337 i 4500 | ||
|---|---|---|---|
| 001 | publ27844 | ||
| 005 | 20240509060011.0 | ||
| 008 | 230711s2023 hu o 000 eng d | ||
| 022 | |a 1471-2598 | ||
| 024 | 7 | |a 10.1080/14712598.2023.2211204 |2 doi | |
| 024 | 7 | |a 33826696 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarlós Patrícia | |
| 245 | 1 | 0 | |a Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease |h [elektronikus dokumentum] : |b results of a multicenter survey / |c Sarlós Patrícia |
| 260 | |c 2023 | ||
| 300 | |a 827-832 | ||
| 490 | 0 | |a EXPERT OPINION ON BIOLOGICAL THERAPY |v 23 No. 8 | |
| 520 | 3 | |a Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.Hungarian patients with inflammatory bowel disease were interviewed after a mandatory non-medical switch from an infliximab (IFX) originator to a biosimilar GP1111 or from an adalimumab (ADA) originator to a biosimilar GP2017. Drug choice was based on patient's and physician's decision. Subjective efficacy was measured using a 10-point scale, and AEs were assessed. Difference in efficacy before and after the switch was compared within and between the drugs.Seventy-three ADA and 106 IFX switching patients were interviewed. Subjective efficacy of IFX biosimilar was rated lower compared to IFX originator (8.72 ± 1.68 vs. 7.77 ± 2.34; p = 0.001). The ADA biosimilar was rated higher than its originator (9.02 ± 1.61 vs. 8.42 ± 1.93; p = 0.017). Patients receiving ADA biosimilar were more satisfied with the new treatment compared to IFX (p = 0.032). The incidence of new AEs was 85% in the ADA and 55% in the IFX group (1.79 vs. 0.93 AEs per patient, respectively, p < 0.001).Subjective efficacy of switching to a biosimilar was proven in case of ADA, while reduced efficacy was experienced with IFX biosimilar. Perception of AEs was high and varied between biosimilars. | |
| 650 | 4 | |a Orvos- és egészségtudomány | |
| 700 | 0 | 1 | |a Bikar Alexander |e aut |
| 700 | 0 | 2 | |a Borbásné Farkas Kornélia |e aut |
| 700 | 0 | 2 | |a Resál Tamás |e aut |
| 700 | 0 | 2 | |a Szepes Zoltán |e aut |
| 700 | 0 | 2 | |a Farkas Klaudia |e aut |
| 700 | 0 | 2 | |a Nagy Ferenc |e aut |
| 700 | 0 | 2 | |a Vincze Áron |e aut |
| 700 | 0 | 2 | |a Miheller Pál |e aut |
| 700 | 0 | 2 | |a Molnár Tamás |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/27844/3/33826696_megjelent.pdf |z Dokumentum-elérés |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/27844/4/33826696_elfogadott.pdf |z Dokumentum-elérés |